Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Third-line Therapy of Multiple Myeloma With Lenalidomide in Combination With Pioglitazone, Dexamethasone and Metronomic Low-dose Chemotherapy With Treosulfan

NCT01010243 is registered in ClinicalTrials.gov with University of Regensburg as lead sponsor.

NCT NCT01010243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Third-line Therapy of Multiple Myeloma With Lenalidomide in Combination With Pioglitazone, Dexamethasone and Metronomic Low-dose Chemotherapy With Treosulfan
Lead sponsor
University of Regensburg
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2009
Completion date
October 31, 2016
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma